Cooper Companies (The) (COO) : 8 brokerage houses believe that Cooper Companies (The) (COO) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Cooper Companies (The) (COO). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 11 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.45.
Cooper Companies (The) (COO) : The most positive equity analysts on Cooper Companies (The) (COO) expects the shares to touch $215, whereas, the least positive believes that the stock will trade at $185 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $201 with an expected fluctuation of $9.09 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Also, In the latest statement by the brokerage house, Jefferies maintains its outlook on Cooper Companies (The) (NYSE:COO). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm raises the price target from $190 per share to $210 per share. The rating by the firm was issued on August 24, 2016.
Cooper Companies (The) (NYSE:COO): The stock opened at $188.08 and touched an intraday high of $189.69 on Wednesday. During the day, the stock corrected to an intraday low of $187.05, however, the bulls stepped in and pushed the price higher to close in the green at $188.56 with a gain of 0.14% for the day. The total traded volume for the day was 376,334. The stock had closed at $188.3 in the previous trading session.
The Cooper Companies, Inc. (Cooper), is a global medical device company. The Company operates through two business units, CooperVision, Inc. (CVI) and CooperSurgical, Inc. (CSI). CooperVision is a global manufacturer providing products for contact lens wearers. CooperSurgical focuses on supplying womens health clinicians with products and treatment options to improve the delivery of healthcare to women. CooperSurgical products fall into three main segments based on the point of healthcare delivery: Hospital, Office and Fertility Clinic. CooperVision develops, manufactures and markets a range of monthly, two-week and single-use contact lenses, featuring advanced materials and optics. CooperVision is involved in correcting vision problems such as astigmatism, presbyopia and ocular dryness, and provides innovative contact lens solutions. The CooperVision Companys brands include Biofinity, Avaira and MyDay and CooperSurgical Companys brands include Advincula Arch, SeeClear and Mobius.